Regulus Therapeutics (RGLS) Getting Somewhat Positive News Coverage, Study Shows

News coverage about Regulus Therapeutics (NASDAQ:RGLS) has trended somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regulus Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.1021894029804 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Several research firms have issued reports on RGLS. Zacks Investment Research cut shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 18th. Chardan Capital reaffirmed a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. Leerink Swann began coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They set an “outperform” rating and a $2.00 price target on the stock. B. Riley began coverage on shares of Regulus Therapeutics in a research note on Wednesday, March 28th. They set a “neutral” rating and a $1.00 price target on the stock. Finally, BMO Capital Markets set a $1.00 price target on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research note on Thursday, March 8th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $2.00.

How to Become a New Pot Stock Millionaire

Shares of RGLS traded down $0.01 during mid-day trading on Thursday, hitting $0.65. The company had a trading volume of 93,848 shares, compared to its average volume of 604,956. Regulus Therapeutics has a 1-year low of $0.63 and a 1-year high of $1.95. The stock has a market capitalization of $69.44, a PE ratio of -0.68 and a beta of 1.69.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.03. Regulus Therapeutics had a negative net margin of 99,868.07% and a negative return on equity of 201.84%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. research analysts expect that Regulus Therapeutics will post -0.64 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Regulus Therapeutics (RGLS) Getting Somewhat Positive News Coverage, Study Shows” was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://ledgergazette.com/2018/04/19/regulus-therapeutics-rgls-getting-somewhat-positive-news-coverage-study-shows.html.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.

Insider Buying and Selling by Quarter for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply